Functional Selectivity: How Different Cannabinoid Drugs Can Activate Different Pathways Through the Same Receptor
Cannabinoid receptor ligands can selectively activate specific signaling pathways while ignoring others, a phenomenon called functional selectivity that could enable safer cannabinoid medicines with fewer side effects.
Quick Facts
What This Study Found
This review examined the concept of functional selectivity (biased agonism) at cannabinoid receptors, a phenomenon where different drugs binding to the same receptor can trigger different cellular responses.
Traditionally, receptors were viewed as simple on/off switches. Functional selectivity reveals they are more like multi-channel dimmer switches: a drug can turn up one signaling pathway while leaving others unchanged or turning them down.
Chemically distinct classes of cannabinoid compounds show measurable signaling bias at CB1 and CB2 receptors, preferentially activating some pathways (like G-protein signaling) while not engaging others (like beta-arrestin recruitment). This selectivity appears to depend on both receptor structural features and ligand chemical properties.
The clinical significance is substantial: the adverse effects of conventional cannabinoid drugs (psychoactivity, tolerance, dependence) may be linked to specific signaling pathways. Designing drugs that avoid those pathways while activating therapeutic ones could produce safer cannabinoid medicines.
Key Numbers
The review covers multiple signaling pathways including Gi/o protein coupling, beta-arrestin recruitment, MAPK/ERK, and intracellular calcium signaling at both CB1 and CB2 receptors.
How They Did This
Review of known CB1 and CB2 signaling pathways, evidence for functional selectivity in response to endogenous and exogenous cannabinoid ligands, and structural features enabling pathway-selective receptor activation.
Why This Research Matters
The clinical failure of several cannabinoid drugs (most notably rimonabant) was caused by engaging detrimental signaling pathways alongside therapeutic ones. Functional selectivity offers a solution: design drugs that activate only the beneficial pathways.
The Bigger Picture
Functional selectivity is revolutionizing drug design across all G-protein coupled receptor targets, not just cannabinoid receptors. For cannabinoid medicine specifically, it offers the most promising path to separating therapeutic effects from psychoactive and adverse effects.
What This Study Doesn't Tell Us
Much functional selectivity data comes from in vitro cell-based assays that may not fully predict in vivo pharmacology. The relationship between specific signaling pathways and clinical outcomes is not yet fully mapped. Designing functionally selective drugs remains technically challenging.
Questions This Raises
- ?Can specific signaling biases reliably predict clinical outcomes (therapeutic vs. adverse effects)?
- ?Could existing cannabinoid compounds be modified to achieve greater functional selectivity?
- ?Would biased agonists at cannabinoid receptors be less prone to tolerance development?
Trust & Context
- Key Stat:
- Different cannabinoid compounds can selectively activate specific pathways at the same receptor
- Evidence Grade:
- Review of established pharmacological concepts applied to cannabinoid receptors. Moderate because functional selectivity is well-documented in vitro but clinical translation is still developing.
- Study Age:
- Published in 2017.
- Original Title:
- Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.
- Published In:
- Biochemical pharmacology, 128, 1-11 (2017)
- Authors:
- Mallipeddi, Srikrishnan, Janero, David R(5), Zvonok, Nikolai(2), Makriyannis, Alexandros
- Database ID:
- RTHC-01447
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is functional selectivity?
It is the phenomenon where different drugs binding to the same receptor can trigger different cellular responses. For cannabinoid receptors, this means it may be possible to design drugs that produce pain relief without psychoactive effects, for example.
How does this help develop better cannabinoid medicines?
If the therapeutic effects of cannabinoids work through one signaling pathway and the side effects through another, a functionally selective drug could activate only the therapeutic pathway. This is the most promising approach to separating cannabinoid benefits from harms.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01447APA
Mallipeddi, Srikrishnan; Janero, David R; Zvonok, Nikolai; Makriyannis, Alexandros. (2017). Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.. Biochemical pharmacology, 128, 1-11. https://doi.org/10.1016/j.bcp.2016.11.014
MLA
Mallipeddi, Srikrishnan, et al. "Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.." Biochemical pharmacology, 2017. https://doi.org/10.1016/j.bcp.2016.11.014
RethinkTHC
RethinkTHC Research Database. "Functional selectivity at G-protein coupled receptors: Advan..." RTHC-01447. Retrieved from https://rethinkthc.com/research/mallipeddi-2017-functional-selectivity-at-gprotein
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.